Skip to menu Skip to content Skip to footer

2019

Conference Publication

PCN95 cost-effectiveness analysis of germline BRCA mutation testing and olaparib treatment in metastatic breast cancer: an evaluation of codependent technologies

Tuffaha, H. and Scuffham, P. (2019). PCN95 cost-effectiveness analysis of germline BRCA mutation testing and olaparib treatment in metastatic breast cancer: an evaluation of codependent technologies. ISPOR Europe 2019, Copenhagen, Denmark, 2-6 November 2019. New York, NY United States: Elsevier. doi: 10.1016/j.jval.2019.09.292

PCN95 cost-effectiveness analysis of germline BRCA mutation testing and olaparib treatment in metastatic breast cancer: an evaluation of codependent technologies

2019

Conference Publication

Cost-effective analysis of supervised exercise training in men with prostate cancer previously treated with androgen deprivation therapy and radiation

Edmunds, Kim, Reeves, Penny, Tuffaha, Haitham, Galvao, Daniel, Newton, Rob, Spry, Nigel, Denham, James, Taaffe, Dennis R., Joseph, David, Lamb, David S., Chambers, Suzanne K. and Scuffham, Paul (2019). Cost-effective analysis of supervised exercise training in men with prostate cancer previously treated with androgen deprivation therapy and radiation. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, SA, Australia, 12–14 November 2019. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.13262

Cost-effective analysis of supervised exercise training in men with prostate cancer previously treated with androgen deprivation therapy and radiation

2019

Conference Publication

Value for money of putting precision into practice: Germline genetic testing to guide olaparib treatment in HER2-negative metastatic breast cancer

Tuffaha, Haitham and Scuffham, Paul (2019). Value for money of putting precision into practice: Germline genetic testing to guide olaparib treatment in HER2-negative metastatic breast cancer. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, Australia, 12–14 November 2019. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.13262

Value for money of putting precision into practice: Germline genetic testing to guide olaparib treatment in HER2-negative metastatic breast cancer

2019

Conference Publication

PCN349 Value of information analysis guiding the reimbursement decision of olaparib for metastatic breast cancer

Tuffaha, H. and Scuffham, P. (2019). PCN349 Value of information analysis guiding the reimbursement decision of olaparib for metastatic breast cancer. ISPOR Europe 2019, Copenhagen, Denmark, November 2019. New York, NY, United States: Elsevier. doi: 10.1016/j.jval.2019.09.544

PCN349 Value of information analysis guiding the reimbursement decision of olaparib for metastatic breast cancer

2018

Conference Publication

Rare Cancers, no Rare Solutions: Risk Sharing Arrangemnts to Reimburse Medicines for Rare Cancers in Australia

Tuffaha, H. and Scuffham, P. (2018). Rare Cancers, no Rare Solutions: Risk Sharing Arrangemnts to Reimburse Medicines for Rare Cancers in Australia. Moving Into Action: Informing Policy and Strengthening Healthcare Systems in Asia-Pacific, Tokyo, Japan, 8-11 September 2018. Elsevier. doi: 10.1016/j.jval.2018.07.839

Rare Cancers, no Rare Solutions: Risk Sharing Arrangemnts to Reimburse Medicines for Rare Cancers in Australia

2018

Conference Publication

Can we prospectively assess the value for money of oncology clinical trials?

Tuffaha, Haitham, Chambers, Suzanne and Scuffham, Paul (2018). Can we prospectively assess the value for money of oncology clinical trials?. COSA's 45th Annual Scientific Meeting, Mesothelioma and Gastro‐Intestinal Cancers: Technology and Genomics, Perth, WA Australia, 13–15 November 2018. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.13089

Can we prospectively assess the value for money of oncology clinical trials?

2018

Conference Publication

Can technology improve medication adherence in older people with dementia?

El-Saifi, Najwan, Moyle, Wendy, Jones, Cindy and Tuffaha, Haitham (2018). Can technology improve medication adherence in older people with dementia?. 16th International Conference, ICOST 2018, Singapore, 10-12 July, 2018. Cham, Switzerland: Springer. doi: 10.1007/978-3-319-94523-1_1

Can technology improve medication adherence in older people with dementia?

2018

Conference Publication

Value For Money, the Overlooked Aspect in Research Funding Decisions

Tuffaha, H., El-Saifi, N. and Scuffham, P. (2018). Value For Money, the Overlooked Aspect in Research Funding Decisions. Moving Into Action: Informing Policy and Strengthening Healthcare Systems in Asia-Pacific, Tokyo, Japan, 8-11 September 2018. Elsevier. doi: 10.1016/j.jval.2018.07.413

Value For Money, the Overlooked Aspect in Research Funding Decisions

2017

Conference Publication

INTERNATIONAL HTA EXPERIENCE WITH TARGETED THERAPY APPROVALS FOR LUNG CANCER

Maraiki, R., Bymes, J., Tuffaha, H. and Hider, M. (2017). INTERNATIONAL HTA EXPERIENCE WITH TARGETED THERAPY APPROVALS FOR LUNG CANCER. NEW YORK: ELSEVIER SCIENCE INC.

INTERNATIONAL HTA EXPERIENCE WITH TARGETED THERAPY APPROVALS FOR LUNG CANCER

2017

Conference Publication

International HTA experience with targeted therapy approvals For lung cancer

Maraiki, F., Byrnes, J., Tuffaha, H. and Hider, M. (2017). International HTA experience with targeted therapy approvals For lung cancer. ISPOR 20th Annual European Congress, Glasgow, United Kingdom, 4-8 November 2017. New York, NY USA: Elsevier. doi: 10.1016/j.jval.2017.08.335

International HTA experience with targeted therapy approvals For lung cancer

2017

Conference Publication

Improving patient access to novel cancer drugs in Australia: are we there yet?

Tuffaha, Haitham and Scuffham, Paul (2017). Improving patient access to novel cancer drugs in Australia: are we there yet?. COSA's 44th Annual Scientific Meeting, Immunotherapy: Molecules and Mountains, Sydney, NSW Australia, 13-15 November 2017. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.

Improving patient access to novel cancer drugs in Australia: are we there yet?

2015

Conference Publication

Health economic modelling for treatments and services in prostate cancer care: a master model for Australia

Gordon, Louisa, Tuffaha, Haitham, Scuffham, Paul and Lowe, Anthony (2015). Health economic modelling for treatments and services in prostate cancer care: a master model for Australia. 2nd Prostate Cancer World Congress (PCWC), Cairns, QLD, Australia, 17-21 August, 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/bju.13196

Health economic modelling for treatments and services in prostate cancer care: a master model for Australia

2014

Conference Publication

COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSES OF NUTRITIONAL SUPPORT IN PREVENTING PRESSURE ULCERS IN HIGH RISK HOSPITALISED PATIENTS

Tuffaha, H. W., Shelley, R., Chaboyer, W., Gordon, L. G. and Scuffham, P. A. (2014). COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSES OF NUTRITIONAL SUPPORT IN PREVENTING PRESSURE ULCERS IN HIGH RISK HOSPITALISED PATIENTS. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jval.2014.08.2150

COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSES OF NUTRITIONAL SUPPORT IN PREVENTING PRESSURE ULCERS IN HIGH RISK HOSPITALISED PATIENTS

2012

Conference Publication

THE EFFECTIVENESS AND COST EFFECTIVENESS OF PLERIXAFOR plus GCSF VERSUS GCSF +/- CHEMOTHERAPY AS SALVAGE MOBILIZATION REGIMENS IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS

Tuffaha, H. W., Hussein, A. A., Sharma, S., Abu-Jazar, H., Al-Rawi, O. S., Saad, A. M., Al-Zaben, A., Hussein, N. and Abdel-Rahman, F. A. (2012). THE EFFECTIVENESS AND COST EFFECTIVENESS OF PLERIXAFOR plus GCSF VERSUS GCSF +/- CHEMOTHERAPY AS SALVAGE MOBILIZATION REGIMENS IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS. BMT Tandem Meeting, San Diego Ca, Feb 01-05, 2012. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.bbmt.2011.12.130

THE EFFECTIVENESS AND COST EFFECTIVENESS OF PLERIXAFOR plus GCSF VERSUS GCSF +/- CHEMOTHERAPY AS SALVAGE MOBILIZATION REGIMENS IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS

2012

Conference Publication

COMPARATIVE COST UTILITY ANALYSIS OF PLERIXAFOR PLUS GCSF VERSUS CYCLOPHOSPHAMIDE PLUS GCSF AS SALVAGE MOBILIZATION REGIMENS IN MULTIPLE MYELOMA PATIENTS

Tuffaha, H. W., Hussein, A. A. and Abdel-Rahman, F. A. (2012). COMPARATIVE COST UTILITY ANALYSIS OF PLERIXAFOR PLUS GCSF VERSUS CYCLOPHOSPHAMIDE PLUS GCSF AS SALVAGE MOBILIZATION REGIMENS IN MULTIPLE MYELOMA PATIENTS. BMT Tandem Meeting, San Diego Ca, Feb 01-05, 2012. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.bbmt.2011.12.132

COMPARATIVE COST UTILITY ANALYSIS OF PLERIXAFOR PLUS GCSF VERSUS CYCLOPHOSPHAMIDE PLUS GCSF AS SALVAGE MOBILIZATION REGIMENS IN MULTIPLE MYELOMA PATIENTS

2012

Conference Publication

Adverse drug reactions in bone marrow transplant patients

Najjar, R., Tuffaha, H., Abdel-Rahman, F., Hussein, A. and Jazar, H. A. (2012). Adverse drug reactions in bone marrow transplant patients. 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), Geneva, Switzerland, 1-4 April, 2012. London, United Kingdom: Nature Publishing Group. doi: 10.1038/bmt.2012.37

Adverse drug reactions in bone marrow transplant patients